Biotech IPOs Raised Record $1.7 Billion in Q1 2026 But Number of Offerings Remains Stubbornly Low

Biotechnology companies raised $1.7 billion through initial public offerings in the first quarter of 2026 — the most of any quarter since 2021 — but the total number of offerings remained at historically subdued levels, according to BioPharma Dive data.

Six companies priced IPOs in Q1 2026, with a median raise of $287.5 million — more than double the amount seen in the same period last year. Three companies raised more than $300 million each, a benchmark rarely achieved since the sector's 2021 peak.

However, the IPO window remains largely closed to preclinical companies. No preclinical biotechs have gone public since 2024. Companies that successfully priced offerings shared common traits: mid-to-late stage clinical programs, large venture funding histories, and focus on hot therapeutic areas like autoimmune diseases and cancer.

"Macro economic factors and a revolving door at the FDA" are keeping IPO volume down, said Jonathan Norris, a managing director at HSBC Innovation Banking. Renaissance Capital cited "surging volatility" including Middle East conflicts as additional headwinds.

Kailera Therapeutics, an obesity drugmaker backed by Hengrui Pharmaceuticals, filed IPO plans on Friday. Six other companies have announced intentions, though none have priced since late February. Investors expect 20 offerings would constitute a "good year" for the sector, up from 2025's total of 11.